Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,315 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the transaction, the insider now owns 50,751 shares of the company’s stock, valued at approximately $2,349,263.79. This trade represents a 4.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS traded up $0.36 during mid-day trading on Thursday, reaching $49.91. 618,361 shares of the stock were exchanged, compared to its average volume of 639,768. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The business has a fifty day moving average price of $48.54 and a 200 day moving average price of $45.06. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The firm has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $44,000. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. FMR LLC lifted its position in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of recent analyst reports. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays decreased their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Jefferies Financial Group increased their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Finally, Guggenheim restated a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.